HealthyAVOC5NCT05009420
Validation of Avocatin b as a Biomarker of Food Intake
A study testing Avocado in people with Healthy, run by Clinical Nutrition Research Center, Illinois Institute of Technology at 1 site in United States.
Trial summary
The primary objectives are to Identify avocatin b (C17 lipid) in plasma of individuals that consumed 1 avocado. Confirm no avocation b present in the plasma of individuals that avoided avocado intake for 7 days. Determine the effect of an overnight fast on avocation b detection. Read more about this study
- Who is it for?
- Ages 25 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Avocado
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- 19 Jul 2021to 31 Dec 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- BMI 25-35
- Males/females
- 25-70 years of age
Who cannot join
- Does not eat avocados for a reason prohibiting them from being willing to eat 1 avocado
- Sensitive/allergic to avocados
- Allergies to latex or oral allergy syndrome
- Unstable medical conditions such as on dialysis for renal disease, cardiac, gastrointestinal, or hepatic disease, cancer (non-melanoma skin cancer >5 years ago acceptable, any cancer site >10yrs without recurrence).
- Pregnant, lactating, intention of pregnancy
- Lost or gained 15 lbs of body weight in last 2 months
- Following restricted or weight loss dietary patterns
- Elevated alcohol intake (7+ drinks/week females; 14+ drinks/week males)
Trial locations and contacts
1 site in 1 country.
United States1 site
Clinical Nutrition Research Center
Chicago, Illinois, 60616
About this study
Official title: Validation of Avocatin b as a Biomarker of Food Intake for Assessing the Acute Consumption of Avocado in Free-living Individuals
The primary objectives are to
- Identify avocatin b (C17 lipid) in plasma of individuals that consumed 1 avocado.
- Confirm no avocation b present in the plasma of individuals that avoided avocado intake for 7 days.
- Determine the effect of an overnight fast on avocation b detection.
Read the detailed description
The proposed study will be conducted in humans according to Good Clinical Practice (GCP) guidelines. All subjects will review and sign an Informed Consent Form approved by the Illinois Institute of Technology's Institutional Review Boards (IRB) prior to screening. SCREENING To learn more about the study and to pre-qualify, potential subjects can call the CNRC or visit the website posted on recruitment flyers or from other recruitment materials. If they call the CNRC, a staff member will provide a brief background on the study and ask a series of questions from a screening questionnaire to see if they may be eligible to participate. The same questionnaire is available on the website and can be filled out by potential subjects online. The screening questionnaire includes self-reported information about health status and lifestyle factors that can be used to determine if someone is not eligible for the study (i.e.: has diabetes, cardiovascular disease, on interfering meds, etc…).
Based on the results of the questionnaires, BMI calculation, and health evaluation, subjects who meet the inclusion and exclusion criteria will be invited to participate in the study. Eligible subjects will be trained on "how to prepare for study visit". This will include instructions for avoiding avocados for at least 7 days prior to the study Visit, fasting overnight (10-12 hours), avoidance of vigorous physical activity, alcoholic and caffeinated beverage consumption for at least 24 hours preceding a study day, maintain regular sleep pattern. If the subject did not get enough sleep during the night preceding a study day, the investigators will reschedule their study day.
STUDY DAY:
Study Day visit will last about 1.5 hours with a 30 minutes follow-up visit 24 h after the start of the study treatment.
On a Study Day visit, subjects will arrive at the clinic after fasting for at least 10 hours and in a well-hydrated and well-rested state. Subjects will be inquired for compliance to avocado-free food at least 7 days prior to study day and details of food intake in the 24-hour period prior to the visit to ensure consistency and compliance with the protocol requirements. After confirming compliance with the [ protocol, anthropometric measurements, vital signs (blood pressure, heart rate, and ear temperature) will be taken.
A finger prick for fasting blood glucose will be done to confirm the fasting status. A licensed healthcare professional (LHCP) will draw a baseline blood sample using a butterfly needle (Timepoint t=0). After completing a baseline blood draw, subjects will receive an avocado and crackers to eat onsite. After consuming the avocado and crackers, subjects will be given a take-home snack and be discharged and scheduled to come to CNR the following day for an additional blood sample. The subject will be instructed to fast overnight (10-12 hours), and the blood collection time will be anchored to 24 h after the start of the study treatment (avocado).
Blood collection: Blood will be collected a total of 2 times during the entire study period. The investigators will collect 4 mL of blood each time. Over the course of the whole study, the total amount of blood collected will be 8 mL, which is way less than what is allowed for a one-time blood donation (~550 mL).
- Conditions
- Healthy
- Being tested
- Avocado
- Keywords
- avocado
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AvocadoOther
avocado served with crackers as breakfast
| Study group | Role | What they receive |
|---|---|---|
| Avocado | Experimental | Identify avocatin b (C17 lipid) in plasma of individuals that consumed 1 avocado. Receives: Other: Avocado |
What is being measured
The primary outcome is the main question the study is designed to answer.
changes in avocatin b (C17 lipid) concentration in plasma in healthy individuals, 24 hours after consumed 1 avocado.
fasting blood sample before eating a avocado compare with fasting blood sample 24 hours after consumed 1 avocado.
Measured: baseline (time point 0) to 24 hours
Secondary outcomes (1)
avocatin b (C17 lipid) concentration in plasma of individuals that avoided avocado intake for 7 days
fasting blood sample after avoiding avocado for 7 days from healthy individuals
Measured: Day-7-Day0
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2021
- Study start19 Jul 2021
- Primary completion31 Dec 2021
- Study completion31 Dec 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Clinical Nutrition Research Center, Illinois Institute of TechnologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Identify avocatin b (C17 lipid) in plasma of individuals that consumed 1 avocado
- Masking
- None (open label)
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Hass Avocado Board
- Responsible party
- Sponsor
- Investigators
- Britt Burton-Freeman, Ph.D, Principal investigator, Illinois Insititute of Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05009420
- Sponsor's protocol ID
- IRB-2021-108
- Acronym
- AVOC5
- Status last verified
- Feb 2023
- First submitted
- 2 Aug 2021
- Last updated
- 9 Feb 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validation of Avocatin b as a Biomarker of Food Intake for Assessing the Acute Consumption of Avocado in Free-living Individuals
- ClinicalTrials.gov ID
- NCT05009420
- Acronym / sponsor ID
- AVOC5 / IRB-2021-108
- Conditions
- Healthy
- Keywords
- avocado
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- Clinical Nutrition Research Center, Illinois Institute of TechnologyIndustry (pharma, biotech, devices)
- Collaborators
- Hass Avocado Board
- Study start
- 19 Jul 2021 (actual)
- Primary completion
- 31 Dec 2021 (actual)
- Study completion
- 31 Dec 2021 (actual)
- First posted
- 17 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objectives are to
- Identify avocatin b (C17 lipid) in plasma of individuals that consumed 1 avocado.
- Confirm no avocation b present in the plasma of individuals that avoided avocado intake for 7 days.
- Determine the effect of an overnight fast on avocation b detection.
Detailed description
The proposed study will be conducted in humans according to Good Clinical Practice (GCP) guidelines. All subjects will review and sign an Informed Consent Form approved by the Illinois Institute of Technology's Institutional Review Boards (IRB) prior to screening. SCREENING To learn more about the study and to pre-qualify, potential subjects can call the CNRC or visit the website posted on recruitment flyers or from other recruitment materials. If they call the CNRC, a staff member will provide a brief background on the study and ask a series of questions from a screening questionnaire to see if they may be eligible to participate. The same questionnaire is available on the website and can be filled out by potential subjects online. The screening questionnaire includes self-reported information about health status and lifestyle factors that can be used to determine if someone is not eligible for the study (i.e.: has diabetes, cardiovascular disease, on interfering meds, etc…).
Based on the results of the questionnaires, BMI calculation, and health evaluation, subjects who meet the inclusion and exclusion criteria will be invited to participate in the study. Eligible subjects will be trained on "how to prepare for study visit". This will include instructions for avoiding avocados for at least 7 days prior to the study Visit, fasting overnight (10-12 hours), avoidance of vigorous physical activity, alcoholic and caffeinated beverage consumption for at least 24 hours preceding a study day, maintain regular sleep pattern. If the subject did not get enough sleep during the night preceding a study day, the investigators will reschedule their study day.
STUDY DAY:
Study Day visit will last about 1.5 hours with a 30 minutes follow-up visit 24 h after the start of the study treatment.
On a Study Day visit, subjects will arrive at the clinic after fasting for at least 10 hours and in a well-hydrated and well-rested state. Subjects will be inquired for compliance to avocado-free food at least 7 days prior to study day and details of food intake in the 24-hour period prior to the visit to ensure consistency and compliance with the protocol requirements. After confirming compliance with the [ protocol, anthropometric measurements, vital signs (blood pressure, heart rate, and ear temperature) will be taken.
A finger prick for fasting blood glucose will be done to confirm the fasting status. A licensed healthcare professional (LHCP) will draw a baseline blood sample using a butterfly needle (Timepoint t=0). After completing a baseline blood draw, subjects will receive an avocado and crackers to eat onsite. After consuming the avocado and crackers, subjects will be given a take-home snack and be discharged and scheduled to come to CNR the following day for an additional blood sample. The subject will be instructed to fast overnight (10-12 hours), and the blood collection time will be anchored to 24 h after the start of the study treatment (avocado).
Blood collection: Blood will be collected a total of 2 times during the entire study period. The investigators will collect 4 mL of blood each time. Over the course of the whole study, the total amount of blood collected will be 8 mL, which is way less than what is allowed for a one-time blood donation (~550 mL).
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Identify avocatin b (C17 lipid) in plasma of individuals that consumed 1 avocado
| Arm | Type | Receives |
|---|---|---|
| Avocado | Experimental | Other: AvocadoIdentify avocatin b (C17 lipid) in plasma of individuals that consumed 1 avocado. |
Who may qualify
- Ages
- 25 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- BMI 25-35
- Males/females
- 25-70 years of age
Key exclusion criteria (8 listed)
- Does not eat avocados for a reason prohibiting them from being willing to eat 1 avocado
- Sensitive/allergic to avocados
- Allergies to latex or oral allergy syndrome
- Unstable medical conditions such as on dialysis for renal disease, cardiac, gastrointestinal, or hepatic disease, cancer (non-melanoma skin cancer >5 years ago acceptable, any cancer site >10yrs without recurrence).
- Pregnant, lactating, intention of pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Avocadoavocado served with crackers as breakfast | Other | Avocado |
Primary outcome
changes in avocatin b (C17 lipid) concentration in plasma in healthy individuals, 24 hours after consumed 1 avocado.
Time frame: baseline (time point 0) to 24 hours
fasting blood sample before eating a avocado compare with fasting blood sample 24 hours after consumed 1 avocado.
1 secondary outcome
avocatin b (C17 lipid) concentration in plasma of individuals that avoided avocado intake for 7 days
Time frame: Day-7-Day0
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2023.
- Individual participant dataSharing planned: No
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Britt Burton-Freeman, Ph.D principal investigator
Illinois Insititute of Technology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Avocado in people with Healthy, run by Clinical Nutrition Research Center, Illinois Institute of Technology at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
changes in avocatin b (C17 lipid) concentration in plasma in healthy individuals, 24 hours after consumed 1 avocado. (time frame: baseline (time point 0) to 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2023.